Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trialResearch in context

Summary: Background: The PHILA study suggests that pyrotinib, trastuzumab, and docetaxel significantly improved progression-free survival (PFS) compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2-positive metastatic breast cancer. In this study, we aimed to investigate...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Shuning Liu, Bo Lan, Yuanyi Wang, Tao Yang, Lixi Li, Hewei Ge, Cheng Zeng, Binghe Xu, Haili Qian, Fei Ma
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2024-11-01
Serie:	EBioMedicine
Soggetti:	PHILA study Pyrotinib Trastuzumab HER2-positive breast cancer
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2352396424004158
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!